These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. Sitter T; Schmidt M; Schneider S; Schiffl H J Nephrol; 2002; 15(3):297-301. PubMed ID: 12113602 [TBL] [Abstract][Full Text] [Related]
4. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study. Chauveau P; Level C; Lasseur C; Bonarek H; Peuchant E; Montaudon D; Vendrely B; Combe C J Ren Nutr; 2003 Apr; 13(2):137-43. PubMed ID: 12671838 [TBL] [Abstract][Full Text] [Related]
5. Procalcitonin as a marker of micro-inflammation in hemodialysis. Conti G; Amore A; Chiesa M; Mancuso D; Cirina P; Mengozzi G; Santoro A; Coppo R J Nephrol; 2005; 18(3):282-8. PubMed ID: 16013016 [TBL] [Abstract][Full Text] [Related]
6. Strong correlation of B2-microglobulin (B2-m) with procalcitonin (PCT) in the serum of chronic hemodialysis patients: a role for infections in the dialysis-related amyloidosis? Kalocheretis P; Revela I; Spanou E; Drouzas A; Makriniotou I; Iatrou C Ren Fail; 2008; 30(3):261-5. PubMed ID: 18350445 [TBL] [Abstract][Full Text] [Related]
7. Procalcitonin in patients undergoing chronic hemodialysis. Schmidt M; Burchardi C; Sitter T; Held E; Schiffl H Nephron; 2000 Feb; 84(2):187-8. PubMed ID: 10657723 [No Abstract] [Full Text] [Related]
8. Is ghrelin a biomarker for mortality in end-stage renal disease? Mak RH; Cheung WW Kidney Int; 2011 Apr; 79(7):697-9. PubMed ID: 21403653 [TBL] [Abstract][Full Text] [Related]
9. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Carrero JJ; Nakashima A; Qureshi AR; Lindholm B; Heimbürger O; Bárány P; Stenvinkel P Kidney Int; 2011 Apr; 79(7):749-56. PubMed ID: 21178976 [TBL] [Abstract][Full Text] [Related]
10. C-reactive protein and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kawaguchi T; Tong L; Robinson BM; Sen A; Fukuhara S; Kurokawa K; Canaud B; Lameire N; Port FK; Pisoni RL Nephron Clin Pract; 2011; 117(2):c167-78. PubMed ID: 20714167 [TBL] [Abstract][Full Text] [Related]
11. Relevance of procalcitonin levels in comparison to other markers of inflammation in hemodialysis patients. Visvardis G; Griveas I; Fleva A; Giannakou A; Papadopoulou D; Mitsopoulos E; Kyriklidou P; Manou E; Ginikopoulou E; Meimaridou D; Pavlitou K; Sakellariou G Ren Fail; 2005; 27(4):429-34. PubMed ID: 16060132 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Chaykovska L; Tsuprykov O; Hocher B Clin Lab; 2011; 57(7-8):455-67. PubMed ID: 21888009 [TBL] [Abstract][Full Text] [Related]
13. C-reactive protein: "cutoff" point and clinical applicability. Tsirpanlis G; Alevyzaki F; Triantafyllis G; Chatzipanagiotou S; Nicolaou C Am J Kidney Dis; 2005 Aug; 46(2):368; author reply 369. PubMed ID: 16112061 [No Abstract] [Full Text] [Related]
14. [Old and new inflammatory biomarkers: what utility for general internist?]. Monti M Rev Med Suisse; 2013 Oct; 9(404):2008-10, 2012. PubMed ID: 24313053 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of C-reactive protein for heart disease in dialysis patients. Wang AY Curr Opin Investig Drugs; 2005 Sep; 6(9):879-86. PubMed ID: 16187687 [TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of the measurement of serum procalcitonin: comparative study of procalcitonin and serum amyloid A protein in patients with high and low concentrations of serum C-reactive protein. Shimetani N; Shimetani K; Mori M Scand J Clin Lab Invest; 2004; 64(5):469-74. PubMed ID: 15276911 [TBL] [Abstract][Full Text] [Related]